{
  "docId": "019de074-1317-767b-825b-77b5f795fc6c",
  "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 44,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to show how patients transition from Study 0169 to 0170.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/11",
  "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
  "deckJsonHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c.json",
  "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.85,
        "x": 0.08,
        "y": 0.12
      },
      "kind": "diagram",
      "text": "Study design flow for 0169 and 0170",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef042afd-39a4-416e-b119-b056fdc49634",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.32,
        "y": 0.065
      },
      "kind": "list",
      "text": "Eligibility criteria for Study 0169 and 0170",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7243c8e5-9602-4f92-82b8-18588bdcc098",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Footnotes regarding study definitions and abbreviations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce1b48a8-011d-4531-bb71-a79d88eda452",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.65,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Sequential Ampreloxetine Phase 3 Studies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4956dbc8-f893-4e9e-b977-6191d5b6ee0a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "a066fe2f-5cfa-43db-8d79-06927b8f7cd5",
      "evidence": "Visual timeline of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "2bf24754-8a89-445c-8223-ba21794de27d",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ampreloxetine as a novel pharmacological strategy for treating nOH, with data on its efficacy and safety.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}